Open AccessPhase II open‐label study of recombinant circularly permuted TRAIL as a single‐agent treatment for relapsed or refractory multiple myeloma
Author(s) -
Leng Yun,
Qiu Lugui,
Hou Jian,
Zhao Yaozhong,
Zhang Xuejun,
Yang Shifang,
Xi Hao,
Huang Zhongxia,
Pan Ling,
Chen Wenming
Publication year - 2016
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-016-0140-0
Subject(s) - neutropenia , medicine , adverse effect , rash , multiple myeloma , toxicity , refractory (planetary science) , leukopenia , gastroenterology , phases of clinical research , oncology , surgery , physics , astrobiology